Karen J. Coffman

An oral SARS-CoV-2 M ^pro inhibitor clinical candidate for the treatment of COVID-19

Dafydd R. Owen, Charlotte Allerton, Annaliesa S. Anderson et al. · Science · 2021 · 1.8K citations · Full text

Viral Diagnostics, Worldwide Outbreak, Immunology +16

Discovery and Preclinical Profiling of 3-[4-(Morpholin-4-yl)-7 <i>H</i> -pyrrolo[2,3- <i>d</i> ]pyrimidin-5-yl]benzonitrile (PF-06447475), a Highly Potent, Selective, Brain Penetrant, and in Vivo Active LRRK2 Kinase Inhibitor

Jaclyn L. Henderson, Bethany L. Kormos, Matthew M. Hayward et al. · Journal of Medicinal Chemistry · 2014 · 178 citations · Full text

Design and Discovery of 6-[(3<i>S</i>,4<i>S</i>)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1,5-dihydro-4<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-one (PF-04447943), a Selective Brain Penetrant PDE9A Inhibitor for the Treatment of Cognitive Disorders

Patrick R. Verhoest, Kari R. Fonseca, Xinjun Hou et al. · Journal of Medicinal Chemistry · 2012 · 71 citations · Full text

Drug Target, Novel Pde9a Inhibitor, Neurochemical Biomarkers +21

A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19

Charlotte Allerton, Joel T. Arcari, Lisa Aschenbrenner et al. · Journal of Medicinal Chemistry · 2024 · 59 citations · Full text

Discovery and Preclinical Characterization of 1-Methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1 <i>H</i> -pyrazolo-[3,4- <i>b</i> ]pyrazine (PF470): A Highly Potent, Selective, and Efficacious Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulator

Lei Zhang, Gayatri Balan, Gabriela Barreiro et al. · Journal of Medicinal Chemistry · 2014 · 51 citations · Full text